Diagnosing, discarding, or de-VUSsing: A practical guide to (un)targeted metabolomics as variant-transcending functional tests

2022 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Diagnosing, discarding, or de-VUSsing: A practical guide to (un)targeted metabolomics as variant-transcending functional tests​
Ferreira, E. A.; Veenvliet, A. R. J.; Engelke, U. F. H.; Kluijtmans, L. A. J.; Huigen, M. C. D. G.; Hoegen, B. & de Boer, L. et al.​ (2022) 
Genetics in Medicine,.​ DOI: https://doi.org/10.1016/j.gim.2022.10.002 

Documents & Media

License

Published Version

Usage license

Details

Authors
Ferreira, Elise A.; Veenvliet, Annemarijne R. J.; Engelke, Udo F. H.; Kluijtmans, Leo A. J.; Huigen, Marleen C. D. G.; Hoegen, Brechtje; de Boer, Lonneke; de Vries, Maaike C.; van Bon, Bregje W.; Leenders, Erika; Coene, Karlien L. M.
Abstract
Purpose For patients with inherited metabolic disorders (IMDs), any diagnostic delay should be avoided because early initiation of personalized treatment could prevent irreversible health damage. To improve diagnostic interpretation of genetic data, gene function tests can be valuable assets. For IMDs, variant-transcending functional tests are readily available through (un)targeted metabolomics assays. To support the application of metabolomics for this purpose, we developed a gene-based guide to select functional tests to either confirm or exclude an IMD diagnosis. Methods Using information from a diagnostic IMD exome panel, Kyoto Encyclopedia of Genes and Genomes, and Inborn Errors of Metabolism Knowledgebase, we compiled a guide for metabolomics-based gene function tests. From our practical experience with this guide, we retrospectively selected illustrative cases for whom combined metabolomic/genomic testing improved diagnostic success and evaluated the effect hereof on clinical management. Results The guide contains 2047 metabolism-associated genes for which a validated or putative variant-transcending gene function test is available. We present 16 patients for whom metabolomic testing either confirmed or ruled out the presence of a second pathogenic variant, validated or ruled out pathogenicity of variants of uncertain significance, or identified a diagnosis initially missed by genetic analysis. Conclusion Metabolomics-based gene function tests provide additional value in the diagnostic trajectory of patients with suspected IMD by enhancing and accelerating diagnostic success.
Issue Date
2022
Journal
Genetics in Medicine 
Organization
Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie ; Klinik für Kinder- und Jugendmedizin ; Universitätsmedizin Göttingen 
ISSN
1098-3600
Language
English
Sponsor
http://dx.doi.org/10.13039/100016062 Stichting Metakids

Reference

Citations


Social Media